Genomic Health, Inc. (GHDX) CEO Kimberly J. Popovits Sells 25,000 Shares

Genomic Health, Inc. (NASDAQ:GHDX) CEO Kimberly J. Popovits sold 25,000 shares of the firm’s stock in a transaction on Tuesday, October 16th. The stock was sold at an average price of $66.26, for a total value of $1,656,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kimberly J. Popovits also recently made the following trade(s):

  • On Tuesday, October 16th, Kimberly J. Popovits sold 50,000 shares of Genomic Health stock. The stock was sold at an average price of $65.28, for a total value of $3,264,000.00.

Shares of NASDAQ:GHDX traded down $2.11 on Friday, hitting $81.67. 1,054,132 shares of the company’s stock were exchanged, compared to its average volume of 332,033. Genomic Health, Inc. has a 12 month low of $26.54 and a 12 month high of $92.18. The company has a market cap of $3.23 billion, a price-to-earnings ratio of 8,167.00 and a beta of 0.44.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Tuesday, November 6th. The medical research company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.07 by $0.28. The firm had revenue of $101.30 million for the quarter, compared to analyst estimates of $94.27 million. Genomic Health had a return on equity of 14.76% and a net margin of 4.95%. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.06) earnings per share. On average, analysts forecast that Genomic Health, Inc. will post 1.06 EPS for the current fiscal year.

GHDX has been the subject of a number of analyst reports. Zacks Investment Research upgraded Genomic Health from a “hold” rating to a “buy” rating and set a $67.00 price target for the company in a research report on Wednesday, August 29th. Piper Jaffray Companies raised their price target on Genomic Health from $34.00 to $50.00 and gave the stock a “neutral” rating in a research report on Friday, July 27th. Canaccord Genuity restated a “buy” rating and issued a $82.00 price target (up from $70.00) on shares of Genomic Health in a research report on Wednesday. Cowen restated a “hold” rating and issued a $50.00 price target on shares of Genomic Health in a research report on Monday, August 6th. Finally, Raymond James started coverage on Genomic Health in a research report on Tuesday, October 23rd. They issued a “market perform” rating for the company. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, two have given a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $48.33.

Several institutional investors have recently made changes to their positions in GHDX. Millennium Management LLC increased its stake in shares of Genomic Health by 114.0% during the second quarter. Millennium Management LLC now owns 1,446,250 shares of the medical research company’s stock valued at $72,891,000 after buying an additional 770,413 shares during the period. Acadian Asset Management LLC increased its stake in shares of Genomic Health by 112.8% during the third quarter. Acadian Asset Management LLC now owns 525,376 shares of the medical research company’s stock valued at $36,891,000 after buying an additional 278,516 shares during the period. Renaissance Technologies LLC increased its stake in shares of Genomic Health by 18.8% during the second quarter. Renaissance Technologies LLC now owns 1,404,924 shares of the medical research company’s stock valued at $70,808,000 after buying an additional 222,324 shares during the period. FMR LLC increased its stake in shares of Genomic Health by 125.5% during the third quarter. FMR LLC now owns 299,542 shares of the medical research company’s stock valued at $21,034,000 after buying an additional 166,681 shares during the period. Finally, Castleark Management LLC purchased a new position in shares of Genomic Health during the second quarter valued at $6,370,000. Hedge funds and other institutional investors own 89.90% of the company’s stock.

WARNING: This story was originally posted by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.baseballdailydigest.com/2018/11/10/kimberly-j-popovits-sells-25000-shares-of-genomic-health-inc-ghdx-stock.html.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Featured Article: Price to Earnings Ratio (PE), For Valuing Stocks

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply